These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 28638029)

  • 1. [Pharmacotherapy of attention deficit hyperactivity disorder in children: the results of a multicenter double-blind placebo-controlled study of hopantenic acid].
    Zavadenko NN; Suvorinova NY; Vakula IN; Malinina EV; Kuzenkova LM
    Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(5):39-45. PubMed ID: 28638029
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Pharmacotherapy of psychomotor developmental delay in 6-12 months preterm infants with hypoxic-ischemic encephalopathy (the double-blind comparative multicenter placebo-controlled study)].
    Zavadenko NN; Guzeva VI; Gaynetdinova DD; Davydova LA; Zavadenko AN; Romanova TA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2019; 119(10):30-39. PubMed ID: 31793540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does Guanfacine Extended Release Impact Functional Impairment in Children with Attention-Deficit/Hyperactivity Disorder? Results from a Randomized Controlled Trial.
    Stein MA; Sikirica V; Weiss MD; Robertson B; Lyne A; Newcorn JH
    CNS Drugs; 2015 Nov; 29(11):953-62. PubMed ID: 26547425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [A strategy for increasing the efficiency of psychopharmacological treatment of hyperkinetic behavior disorder with pantogam].
    Kupriyanova TA; Koren EV; Alabusheva NN
    Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(11. Vyp. 2):75-79. PubMed ID: 29359723
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
    Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Attention-deficit hyperactivity disorder: determination of the optimal medical treatment duration].
    Zavadenko NN; Suvorinova NIu
    Zh Nevrol Psikhiatr Im S S Korsakova; 2011; 111(10 Pt 1):28-32. PubMed ID: 22500309
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder: results of a randomized, double-blind, placebo-controlled, flexible-dose study.
    Biederman J; Swanson JM; Wigal SB; Kratochvil CJ; Boellner SW; Earl CQ; Jiang J; Greenhill L
    Pediatrics; 2005 Dec; 116(6):e777-84. PubMed ID: 16322134
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical and neurophysiological manifestations of sluggish cognitive tempo in children].
    Chutko LS; Yakovenko EA; Surushkina SY; Anisimova TI; Cherednichenko DV; Didur MD; Chekalova SA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2024; 124(5):120-127. PubMed ID: 38884438
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized, Double-Blind, Placebo-Controlled Acute Comparator Trials of Lisdexamfetamine and Extended-Release Methylphenidate in Adolescents With Attention-Deficit/Hyperactivity Disorder.
    Newcorn JH; Nagy P; Childress AC; Frick G; Yan B; Pliszka S
    CNS Drugs; 2017 Nov; 31(11):999-1014. PubMed ID: 28980198
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Efficacy and tolerability of pantogam activ in patients with partial epilepsy].
    Poverennova IE; Iakunina AV; Kalinin VA; Savel'eva NN
    Zh Nevrol Psikhiatr Im S S Korsakova; 2011; 111(2):54-9. PubMed ID: 21350425
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of Methylphenidate Hydrochloride Extended-Release Capsules (Aptensio XR™) in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Phase III, Randomized, Double-Blind Study.
    Wigal SB; Nordbrock E; Adjei AL; Childress A; Kupper RJ; Greenhill L
    CNS Drugs; 2015 Apr; 29(4):331-40. PubMed ID: 25877989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Pantogam augmentation in hyperkinetic behavior disorder treatment].
    Kupriyanova TA; Koren EV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2016; 116(6):66-69. PubMed ID: 27456906
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Results of a multicentre double-blind randomised placebo-controlled clinical trial evaluating the efficacy and safety of Mexidol in the treatment of Attention Deficit Hyperactivity Disorder in Children (MEGA)].
    Zavadenko NN; Suvorinova NY; Batysheva TT; Bykova OV; Platonova AN; Gaynetdinova DD; Levitina EV; Mashin VV; Vakula IN; Maximova NE
    Zh Nevrol Psikhiatr Im S S Korsakova; 2022; 122(4):75-86. PubMed ID: 35485068
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Randomized, Placebo-Controlled Trial of Guanfacine Extended Release in Adolescents With Attention-Deficit/Hyperactivity Disorder.
    Wilens TE; Robertson B; Sikirica V; Harper L; Young JL; Bloomfield R; Lyne A; Rynkowski G; Cutler AJ
    J Am Acad Child Adolesc Psychiatry; 2015 Nov; 54(11):916-25.e2. PubMed ID: 26506582
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Treatment of attention deficit hyperactivity disorder in children: results of a multicenter, randomized, double-blind, placebo-controlled clinical trial].
    Zavadenko NN; Makushkin EV; Gaynetdinova DD; Kolokolov OV; Malinina EV; Antipenko EA; Sagutdinova ES; Khaletskaya OV; Dmitriev AV; Maslova NN; Mashin VV; Panteleeva MV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2022; 122(11):62-68. PubMed ID: 36440779
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Efficacy of pantogam in the treatment of hyperkinetic disorders in children].
    Sukhotina NK; Konovalova VV; Kryzhanovskaia IL; Kupriianova TA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2010; 110(12):24-8. PubMed ID: 21311483
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atomoxetine versus placebo in children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: a double-blind, randomized, multicenter trial in Germany.
    Dittmann RW; Schacht A; Helsberg K; Schneider-Fresenius C; Lehmann M; Lehmkuhl G; Wehmeier PM
    J Child Adolesc Psychopharmacol; 2011 Apr; 21(2):97-110. PubMed ID: 21488751
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Pantogam activ (D-, L-hopantenic acid) in the treatment of cognitive and anxiety disorders in patients with arterial hypertension].
    Smulevich AB; Volel BA; Ternovaya ES; Nikitina YM
    Zh Nevrol Psikhiatr Im S S Korsakova; 2015; 115(12):40-49. PubMed ID: 26978493
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of extended-release guanfacine hydrochloride in children and adolescents with attention-deficit/hyperactivity disorder: a randomized, controlled, phase III trial.
    Hervas A; Huss M; Johnson M; McNicholas F; van Stralen J; Sreckovic S; Lyne A; Bloomfield R; Sikirica V; Robertson B
    Eur Neuropsychopharmacol; 2014 Dec; 24(12):1861-72. PubMed ID: 25453486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of Ritalin LA, a new, once daily, extended-release dosage form of methylphenidate, in children with attention deficit hyperactivity disorder.
    Biederman J; Quinn D; Weiss M; Markabi S; Weidenman M; Edson K; Karlsson G; Pohlmann H; Wigal S
    Paediatr Drugs; 2003; 5(12):833-41. PubMed ID: 14658924
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.